STOCK TITAN

Inotiv, Inc. to Report Fiscal 2023 First Quarter Financial Results and Host Conference Call on Monday, February 13, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Inotiv, Inc. (NASDAQ: NOTV) will announce its financial results for the first quarter of fiscal 2023, ended December 31, 2022, on February 13, 2023, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results. Participants can dial (877) 407-9753 for domestic calls and (201) 493-6739 internationally. The call will also be available via webcast on the Investors section of Inotiv's website.

Inotiv is a contract research organization focused on drug discovery and development services. The company supports R&D projects while striving to enhance efficiency and reduce costs.

Positive
  • Scheduled conference call for Q1 fiscal 2023 results indicates proactive investor communication.
Negative
  • Potential risks from recent non-human primate matters affecting business and operations.

WEST LAFAYETTE, Ind., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2023 first quarter ended December 31, 2022 on Monday, February 13, 2023 after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.

Interested parties may participate in the call by dialing:

  • (877) 407-9753 (Domestic)
  • (201) 493-6739 (International)

The live conference call webcast will be accessible in the Investors section of the Company’s web site and directly via the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=7fu8sVnU

For those who cannot listen to the live broadcast, an online replay will be available in the Investors section of Inotiv’s web site at: https://www.inotivco.com/investors/investor-information/.

About Inotiv

Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotivco.com/.

This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to the impact of recent events related to non-human primate matters on the Company’s business, operations, results, financial condition, cash flows, and assets, the Company’s ability to comply with covenants under its credit agreement, changes in the market and demand for the Company’s products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, governmental regulations, inspections and investigations, claims and litigation against or involving the Company, its business and/or its industry, the impact of site closures and consolidations, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.

Company Contact Investor Relations
Inotiv, Inc. The Equity Group Inc.
Beth A. Taylor, Chief Financial Officer Devin Sullivan
(765) 497-8381 (212) 836-9608
btaylor@inotivco.com dsullivan@equityny.com


FAQ

When will Inotiv announce its Q1 2023 financial results?

Inotiv will announce its Q1 2023 financial results on February 13, 2023, after market close.

What time is Inotiv's conference call for Q1 2023 results?

The conference call will take place at 4:30 p.m. ET on February 13, 2023.

How can I participate in Inotiv's Q1 2023 financial results conference call?

You can participate by dialing (877) 407-9753 for domestic calls or (201) 493-6739 for international calls.

What is the focus of Inotiv's services?

Inotiv specializes in nonclinical and analytical drug discovery and development services.

What risks does Inotiv face according to the recent press release?

Inotiv faces potential risks related to recent non-human primate matters that could impact its business and operations.

Inotiv, Inc.

NASDAQ:NOTV

NOTV Rankings

NOTV Latest News

NOTV Stock Data

85.78M
22.26M
13.48%
13.92%
4.97%
Diagnostics & Research
Services-commercial Physical & Biological Research
Link
United States of America
WEST LAFAYETTE